Breakthrough Eye Therapy

Our innovative non-viral gene therapy platform offers revolutionary treatments for eye diseases.
Innovative Drug Delivery Platform

Leveraging the Power of Electroporation

Eyevensys technology features proprietary DNA plasmids and our proprietary Electrotransfection System,
comprising an ocular device and an electrical pulse generator.

DNA Plasmids

Proprietary DNA plasmids encoding therapeutic proteins targeting retinal disease pathways are designed and produced by Eyevensys.

Electrotransfection System

Delivers DNA plasmids to the ciliary muscle cell nuclei, where therapeutic proteins are expressed and secreted, reaching the back of the eye.

BREAKTHROUGH TECHNOLOGY

Our proprietary technology enables the eye to generate its own therapeutic proteins.

Our Technology
OUR PIPELINE

EYS809

A novel approach for the
treatment of Wet AMD, our
platform technology enables
production of two powerful
proteins by encoding a single
plasmid.

Explore Our Pipeline

News

The latest Eyevensys news, press releases, and more

Eyevensys Receives FDA Orphan Drug Designation for EYS611 for Treatment of Retinitis Pigmentosa

 Eyevensys Receives FDA Orphan Drug Designation for EYS611 for Treatment of Retinitis Pigmentosa 1920 1080 Eyevensys

Paris, France, and Cambridge, Mass., United States, October 05, 2020 – Eyevensys, a privately held, clinical-stage biotechnology company developing non-viral gene therapies…

Eyevensys Announces Executive Leadership Team Expansion

 Eyevensys Announces Executive Leadership Team Expansion 1920 1277 Eyevensys

Gerald Cagle, Ph.D. named Chairman of the Board Francine Behar-Cohen, M.D., Ph.D. named Chief Innovation Officer Thierry Bordet, Ph.D. named Chief Scientific Officer Paris, France,…

Eyevensys Closes $30M Series B Financing

 Eyevensys Closes $30M Series B Financing 1920 1281 Eyevensys

Eyevensys announced today that it has completed a $30 million Series B financing. The round was led by Boehringer Ingelheim Venture Fund and included participation…

Eyevensys Presents Initial Data from Phase I/II, Non-Viral Gene Therapy for Ocular Diseases

 Eyevensys Presents Initial Data from Phase I/II, Non-Viral Gene Therapy for Ocular Diseases 1920 1281 Eyevensys

Eyevensys this week presented results from part 1 of its phase I/II study for non-infectious uveitis (NIU) at the Ophthalmology Innovation Summit’s (OIS) 11th Annual…

Eyevensys Appoints New Board Member, Gerald Cagle

 Eyevensys Appoints New Board Member, Gerald Cagle 1920 1280 Eyevensys

Eyevensys today announced that Gerald (Jerry) Cagle, Ph.D., former Senior Vice President and Chief Scientific Officer at Alcon Laboratories has joined its Board  of Directors.…

Eyevensys Appoints Dr. Patricia Zilliox as Chief Executive Officer

 Eyevensys Appoints Dr. Patricia Zilliox as Chief Executive Officer 1667 2500 Eyevensys

Paris (France), December 12th, 2017 – Eyevensys, a clinical stage biotech company developing non-viral gene therapies for ophthalmic diseases, today announced the appointment of Dr.…

Eyevensys Appoints Thierry Bordet Ph.D. as Pre-Clinical Director

 Eyevensys Appoints Thierry Bordet Ph.D. as Pre-Clinical Director 1668 2500 Eyevensys

Paris (France), 13th September 2017 – Eyevensys, a clinical stage biotech company developing its proprietary EyeCET platform, the first non-viral gene expression technology that enables…

Eyevensys Appoints Dr Ronald R. Buggage as Chief Medical Officer

 Eyevensys Appoints Dr Ronald R. Buggage as Chief Medical Officer 2500 1667 Eyevensys

Paris (France), 4th September 2017 – Eyevensys, a clinical stage biotech company developing its proprietary EyeCET platform, the first non-viral gene expression technology that enables…

Eyevensys Announces the First-in-Human Treatment with its GroundBreaking EyeCET ElectroTransfection Technology for Eye Diseases

 Eyevensys Announces the First-in-Human Treatment with its GroundBreaking EyeCET ElectroTransfection Technology for Eye Diseases 2500 1667 Eyevensys

Eyevensys announces today that it has successfully treated the first patient in a first-in-human phase I/II trial of its lead candidate EYS606 for Non-Infectious Uveitis…

Eyevensys Receives Approval from the UK Medicines and Healthcare products Regulatory Agency to advance its EyeCET platform into clinical development

 Eyevensys Receives Approval from the UK Medicines and Healthcare products Regulatory Agency to advance its EyeCET platform into clinical development 2500 1668 Eyevensys

Eyevensys, a private biotechnology company developing its proprietary EyeCET platform, the first non-viral gene expression technology that enables the safe, local, sustained production of therapeutic…


Publications 

The latest Eyevensys Scientific Publications
Transferrin Non-Viral Gene Therapy for Treatment of Retinal Degeneration

Karine Bigot, Pauline Gondouin, Romain Bénard, Pierrick Montagne, Jenny Youale,
Marie Piazza, Emilie Picard, Thierry Bordet,* and Francine Behar-Cohen

Long-term efficacy of ciliary muscle gene transfer of three sFlt-1 variants in a rat model of laser-induced choroidal neovascularization.

El Sanharawi M, Touchard E, Benard R, Bigey P, Escriou V, Mehanna C, Naud MC, Berdugo M, Jeanny JC, Behar-Cohen F. Gene Ther, 2013. 20(11):1093-103.

Non-viral gene therapy for GDNF production in RCS rat: the crucial role of the plasmid dose.

Touchard E, Heiduschka P, Berdugo M, Kowalczuk L, Bigey P, Chahory S, Gandolphe C, Jeanny JC, Behar-Cohen F.
Gene Ther, 2012. 19(9):886-98.

The ciliary smooth muscle electrotransfer: basic principles and potential for sustained intraocular production of therapeutic proteins.

Touchard E, Kowalczuk L, Bloquel C, Naud MC, Bigey P, Behar-Cohen F.
J Gene Med, 2010. 12(11):904-19.

Protein delivery for retinal diseases: from basic considerations to clinical applications.

El Sanharawi M, Kowalczuk L, Touchard E, Omri S, de Kozak Y, Behar-Cohen F.
Prog Retin Eye Res, 2010. 29(6):443-65. Review.

Effects of ciliary muscle plasmid electrotransfer of TNF-alpha soluble receptor variants in experimental uveitis.

Touchard E, Bloquel C, Bigey P, Kowalczuk L, Jonet L, Thillaye-Goldenberg B, Naud MC, Scherman D, de Kozak Y, Benezra D, Behar-Cohen F.
Gene Ther, 2009. 16(7):862-73.

Local ocular immunomodulation resulting from electrotransfer of plasmid encoding soluble TNF receptors in the ciliary muscle.

Kowalczuk L, Touchard E, Camelo S, Naud MC, Castaneda B, Brunel N, Besson-Lescure B, Thillaye-Goldenberg B, Bigey P, BenEzra D, de Kozak Y, Behar-Cohen F.
Invest Ophthalmol Vis Sci, 2009. 50(4):1761-8.

Electrically assisted ocular gene therapy.

Bejjani RA, Andrieu C, Bloquel C, Berdugo M, BenEzra D, Behar-Cohen F.
SurvOphthalmol, 2007. 52(2):196-208. Review.

Non-viral ocular gene therapy: potential ocular therapeutic avenues.

Bloquel C, Bourges JL, Touchard E, Berdugo M, BenEzra D, Behar-Cohen F.
Adv Drug DelivRev, 2006. 58(11):1224-42. Review.

Plasmid electrotransfer of eye ciliary muscle: principles and therapeutic efficacy using hTNF-alpha soluble receptor in uveitis.

Bloquel C, Bejjani R, Bigey P, Bedioui F, Doat M, BenEzra D, Scherman D, Behar-Cohen F.
FASEB J, 2006. 20(2):389-91.

Start Typing